Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Integer Holdings Corporation

ITGR

Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.00 – $0.00
Volume 0
Market cap $4.32B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.32B
Price / earnings
41.63×
Price / book
2.5×
Price / sales
2.36×
EV / sales
3.05×
EV / EBITDA
18.01×

Profitability

Earnings per share
$3.05
Return on assets
3.06%
Return on equity
6.01%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.73×
Current ratio
3.98×
Quick ratio
2.6×
Cash ratio
0.07×

Cash flow

Price / cash flow
24.46×
Price / free cash flow
52.76×
Free cash flow
$81.82M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ITGR, quarterly periods
Line itemQ3 FY2026 Oct 2, 2026Q2 FY2026 Jul 3, 2026Q1 FY2026 Apr 3, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 26, 2025Q2 FY2025 Jun 27, 2025Q1 FY2025 Mar 28, 2025Q4 FY2024 Dec 31, 2024
Revenue$449.66M$464.11M$439.58M$472.06M$467.69M$476.49M$437.39M$449.5M
Cost of revenue$348.1M$351.17M$329.99M$347.3M$341.53M$347.34M$317.07M$332.7M
Gross profit$101.56M$112.94M$109.6M$124.76M$126.16M$129.15M$120.32M$116.8M
Selling, general and administrative$54.15M$57.7M$58.71M$57.21M$50.45M$52.92M$51.16M$47.47M
Research and development$13.53M$11.28M$16.24M$10.11M$10.95M$14.24M$14.2M$10.61M
Total operating expenses$73.35M$78.41M$77.73M$68.82M$69.72M$69.81M$70.77M$59.76M
Operating income$28.21M$34.53M$31.87M$55.94M$56.44M$59.34M$49.55M$57.03M
Interest expense-$9.7M-$10.14M-$9.73M-$9.28M-$9.37M-$9.75M-$14.81M-$13.23M
Income before taxes$17.51M$23.29M$20.35M$46.81M$45.99M$45.6M-$13M$39.26M
Income taxes$2.53M-$314K$3.85M-$1.8M$6.31M$8.59M$9.47M$6.29M
Net income$14.98M$23.61M$16.51M$48.61M$39.68M$37.01M-$22.47M$32.7M
Net income attributable to common shareholders$14.98M$23.61M$16.51M$48.61M$39.68M$37.01M-$22.47M$32.7M
EBITDA$68.24M$78.5M$69.65M$92.94M$97.8M$94.28M$84.79M$87.64M
Basic earnings per share$0.44$0.69$0.48$1.39$1.13$1.06-$0.66$0.97
Diluted earnings per share$0.43$0.69$0.48$1.31$1.11$1.04-$0.66$0.90

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Integer (ITGR) Q3 Earnings and Revenues Miss Estimates

Integer Holdings (ITGR) reported Q3 2026 earnings of $1.34 per share, missing the consensus estimate of $1.65 and down from $1.79 year-ago. Revenue of $449.66 million also fell short of expectations and declined from $467.69 million year-over-year. The company received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions. Despite outperforming the S&P 500 by 61.4% year-to-date, the Medical-Instruments industry remains in the bottom 40% of Zacks-ranked industries.

Zacks Investment Research

Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates

Thermo Fisher Scientific (TMO) reported quarterly earnings of $6.68 per share, beating consensus estimates of $6.4 and surpassing revenue expectations at $12.14 billion. The company has outperformed the market by 17.3% year-to-date and maintains a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Integer Holdings (ITGR), another medical device company, is expected to report declining earnings and revenues in its upcoming quarter.

Zacks Investment Research

Is the Options Market Predicting a Spike in Integer Holdings Stock?

Integer Holdings Corporation (ITGR) is drawing attention from options traders due to high implied volatility in its Dec. 18, 2026 $65 Put options, suggesting market expectations for significant price movement. The company holds a Zacks Rank #3 (Hold) rating in the Medical-Instruments industry, with analyst consensus estimates remaining relatively stable around $1.65-$1.66 per share for the current quarter.

GlobeNewswire Inc.

Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

Zacks Investment Research

GMED vs. ITGR: Which Stock Is the Better Value Option?

In a comparison of two medical instruments stocks, Globus Medical (GMED) emerges as the superior value option over Integer (ITGR). GMED holds a Zacks Rank of #1 (Strong Buy) with improving earnings outlook, while ITGR has a Zacks Rank of #3 (Hold). GMED also demonstrates better valuation metrics with a forward P/E of 15.18 versus ITGR's 20.74, and a PEG ratio of 1.22 compared to ITGR's 2.40, earning GMED a Value grade of B versus ITGR's C.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.